Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung

Hussein A. Assi, Sukhmani K. Padda

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Neuroendocrine tumors of the lung are a diverse group of diseases with distinct pathological, molecular, and clinical characteristics. The most recent World Health Organization (WHO) classification identifies two types of high-grade neuroendocrine carcinomas of the lung: small cell lung carcinoma (SCLC), and the less common large cell neuroendocrine carcinoma of the lung (LCNEC). Systemic treatments for these aggressive tumors have largely remained unchanged for years. With the advancement in genomic sequencing and identification of novel targetable pathways over the last decade, a myriad of therapeutic options have emerged, addressing unmet needs for this patient population. In this review, we summarize the latest advances in the management of SCLC and LCNEC, and discuss promising endeavors in development.

Original languageEnglish
Article number100167
Pages (from-to)100167
JournalCancer Treatment and Research Communications
Volume23
Early online dateDec 16 2020
DOIs
StatePublished - 2020

Fingerprint

Dive into the research topics of 'Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung'. Together they form a unique fingerprint.

Cite this